Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Current Leases (2019 - 2025)

Cue Biopharma's Current Leases history spans 7 years, with the latest figure at $2.0 million for Q3 2025.

  • For Q3 2025, Current Leases fell 29.84% year-over-year to $2.0 million; the TTM value through Sep 2025 reached $2.0 million, down 29.84%, while the annual FY2024 figure was $3.5 million, 5.11% up from the prior year.
  • Current Leases for Q3 2025 was $2.0 million at Cue Biopharma, down from $2.1 million in the prior quarter.
  • Across five years, Current Leases topped out at $5.4 million in Q1 2022 and bottomed at $100300.0 in Q4 2022.
  • The 5-year median for Current Leases is $3.4 million (2023), against an average of $3.4 million.
  • The largest annual shift saw Current Leases crashed 97.97% in 2022 before it surged 3257.93% in 2023.
  • A 5-year view of Current Leases shows it stood at $4.9 million in 2021, then plummeted by 97.97% to $100300.0 in 2022, then soared by 3257.93% to $3.4 million in 2023, then grew by 5.11% to $3.5 million in 2024, then plummeted by 42.63% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Current Leases are $2.0 million (Q3 2025), $2.1 million (Q2 2025), and $3.6 million (Q1 2025).